Opioid-induced nausea and vomiting (OINV) represent a frequent and clinically significant complication in patients with cancer. They negatively affect adherence to analgesic therapy, pain control, and overall quality of life. Their pathophysiology is multifactorial and involves activation of the chemoreceptor trigger zone through dopaminergic and serotonergic pathways, impairment of gastrointestinal motility leading...
No actionable change for audiology practice; this article addresses opioid-induced nausea and vomiting in oncology and has no meaningful clinical relevance to hearing health.
This article has minimal relevance to the audiology field; it appears in this feed likely due to indexing overlap and can be deprioritised by audiology readers.
- 01Narrative review published in Cureus on opioid-induced nausea and vomiting (OINV) in cancer patients.
- 02Focuses on how OINV reduces analgesic (pain medicine) adherence in oncology settings.
- 03No direct audiology, hearing loss, or vestibular content identified.
- 04Opioids have known ototoxic (hearing-damaging) potential, but this review does not address that angle.
- 05Audiologists involved in ototoxicity monitoring programmes may note tangential relevance only.
- PMID
- 42291947
- DOI
- 10.7759/cureus.108798.
- Journal
- Cureus
- Publication type
- review
- Evidence level
- 5
- Population
- Cancer patients receiving opioid analgesics
- Intervention
- Opioid analgesics
Primary outcomes
Incidence and management of opioid-induced nausea and vomiting; Impact on analgesic adherence